<- Go Home
Imago BioSciences, Inc.
Imago BioSciences, Inc. operates as a clinical-stage biopharmaceutical company that develops small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that is used in the production of blood cells in the bone marrow. The company was incorporated in 2012 and is based in Redwood City, California. As of January 11, 2023, Imago BioSciences, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Market Cap
$1.2B
Volume
182.9K
Cash and Equivalents
$7.3M
EBITDA
-$62.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$36.09
52 Week Low
$11.56
Dividend
N/A
Price / Book Value
7.05
Price / Earnings
-19.70
Price / Tangible Book Value
7.05
Enterprise Value
$1.0B
Enterprise Value / EBITDA
-16.58
Operating Income
-$62.9M
Return on Equity
30.74%
Return on Assets
-18.55
Cash and Short Term Investments
$178.4M
Debt
N/A
Equity
$172.6M
Revenue
N/A
Unlevered FCF
-$28.2M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium